The Immune Space


Empirical testing of candidate vaccines has led to the successful development of a number of lifesaving vaccines.  With the advent of new tools to decipher three dimensional structures of key antigens, and recombinant methodologies that have led to a veritable explosion of potential vaccine designs, the selection of candidate vaccines suitable for large-scale efficacy testing has become challenging.  This is especially true for diseases such as dengue, HIV, and tuberculosis where there is no validated animal model or correlate of immune protection.  Establishing criteria to select promising vaccine candidates, and understand, early on, their potential for clinical benefit is an imperative. 

An ad hoc group of clinical collaborators, with support from the Global HIV Vaccine Enterprise developed an Immune Space template, to help researchers and funders in determining if and how a vaccine candidate differs from others that have preceded it into efficacy testing.  The template provides a standardized approach by which the character, level and durability of immune responses elicited in early human trials by a candidate vaccine can be described.  

Assays included are divided into "core" - recommended to be performed in every phase I/II trial and "nice-to-have".  For the full list of assays click here.

The immune space concept was developed by Clinical Trial Collaborators and published open access in AIDS Research and Human Retroviruses (ARHR).

Get Involved -- Add Your Results to Our Examples.

By contributing your results to the template, the field will have a more robust reference to evaluate how to move concepts forward.  For more information or to add your results to our template, email Amapola Manrique at [email protected]

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account